IMU (ASX) Why IMU is a multi multi bagger

Originally posted by troutfisho: ↑

This was posted by the CEO of RAC, Dr Daniel Tillet, a few days ago.
It’s refreshing to see, and a commentary on the biotech sector in general. It was started as a post
‘Why doesn’t RAC raise more capital ?’

This is a question that comes up on fairly regular basis, so I thought I would answer it in a dedicated thread. Quite a number of ASX listed biotechs raise and spend huge amount of capital running multiple clinical trials as once (and issuing billions of shares in the process), so why doesn't RAC do the same if it has so many great opportunities? There are a number of reasons for this:

1. Raising and spending more than 10% of your market cap per year is unsustainable. Companies that spend more than this quickly end up in a death spiral of a falling SP with ever more shares being issued just to keep the spending going. If you have a MC of around $400m and you are spending $150m a year this can't be sustained for any length of time. While many shareholders don't understand all the science, even those investors that failed Year 7 science understand the effects of massive dilution on the SP.

2. Biotech spending rises as clinical programs progress. Preclinical research is cheaper than a Phase 1 trial and Phase 1 trials are cheaper than Phase 2, etc. If you start out with a very high rate of spending then this will only grow over time as your IP progresses down the clinical pipeline. If your programs are successful and your SP rises then you can sustain higher spending, but if you let your spending rise faster than your SP you will end up in trouble at some point.

3. Biotech is very cyclical. If you spend like the good times will last forever you will run into trouble. You can't put biotech programs on care & maintenance like you can with a mine when the market turns, once you start a trial you must have the funds to finish it. More than one biotech company has fallen into the trap of starting a trial without having the cash to finish and ended up broke.

4. Biotech in Australia will only mature if investors make a return commensurate with the risk. Many investors in Australia won't touch biotech companies because they have been burnt by companies that have failed to deliver a return. If you run a biotech company here in Australia and selfishly don't worry about generating a return for your investors, you are ultimately damaging the whole sector. When investors make money investing in biotech they will invest in new biotechs, if they lose money they will avoid the sector altogether. The major limiting factor in the Australian biotech sector is a lack of patient capital and this can only be fixed by generating real returns for investors.

At Race we are unapologetic in making our investors a good return our primary commercial focus. Yes we want to help patients and bring bisantrene back to the clinic as soon as we can as we think this will help many, many people, but if we do this in a selfish way we will just damage the whole biotech sector and prevent other amazing drugs and treatments from being funded. Sometimes the fastest way to a good outcome involves considering the wider picture. We are going as fast as can be sustained over the long term.

Disc:I don’t hold RAC but hold several biotechs.

Expand

such pearls of wisdom from tillet.
I’m sure mason upvoted it.

No.	Vol.	Price($)
54	7835902	5.1¢

No.

Vol.

Price($)

7835902

5.1¢

Price($)	Vol.	No.
5.2¢	11705865	9

Price($)

Vol.

No.

5.2¢

11705865

No.	Vol.	Price($)
53	6855510	0.051
96	6675097	0.050
24	3870500	0.049
18	1325211	0.048
5	417000	0.047

No.

Vol.

Price($)

6855510

0.051

6675097

0.050

3870500

0.049

1325211

0.048

417000

0.047

Price($)	Vol.	No.
0.052	11705865	9
0.053	1323676	9
0.054	599025	4
0.055	2013608	13
0.056	790463	9

Price($)

Vol.

No.

0.052

11705865

0.053

1323676

0.054

599025

0.055

2013608

0.056

790463

(20min delay)
Last 5.1¢		Change -0.002(3.77%)		Mkt cap ! $379.2M

Open	High	Low	Value	Volume
5.3¢	5.3¢	5.1¢	$1.015M	19.58M

Why IMU is a multi multi bagger, page-26244

Chalice jumps on Putin nickel export ban threat – but then there's bad news

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

3 stocks with antimony news on Thursday

GTI extends uranium mineralisation at Lo Hema through development drilling

Clarity progresses SECuRE trial with positive safety results

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Why IMU is a multi multi bagger, page-26244

Top Stories

Chalice jumps on Putin nickel export ban threat – but then there's bad news

Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3

3 stocks with antimony news on Thursday

GTI extends uranium mineralisation at Lo Hema through development drilling

Clarity progresses SECuRE trial with positive safety results

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News